A phase I/II trial assessing TGL-100 in head and neck squamous cell carcinoma (HNSCC) patients with recurrent metastatic disease
Latest Information Update: 06 Aug 2020
At a glance
- Drugs TGL-100 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 06 Aug 2020 New trial record
- 29 Jul 2020 According to a Cancer Research UK media release, Cancer Research UK Centre for Drug Development will sponsor and manage this study.